Long-term safety study for ustekinumab vs other biologics
Treatments studied
Part of Digestive system clinical trials.
This study follows adults with Crohn’s disease or ulcerative colitis to compare the long-term safety of ustekinumab against other biologic medicines. It may help show how safe these treatments are over time, using medical records.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18 or older) when you start the study medicine
- You have Crohn’s disease or ulcerative colitis confirmed in your records
- You are starting ustekinumab or a comparison biologic during the study time window
- You have at least 1 year of prior enrollment history in the DoD electronic health record system
- You have no history (in your records) of HIV, organ/tissue transplant, or any cancer (except non-melanoma skin cancer) before or at starting
- You have not been diagnosed with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis in the last 12 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study uses a special camera to track how ustekinumab (a common biologic medicine) spreads in inflamed tissue. It aims to help researchers understand where the drug goes in Crohn’s disease and psoriasis, especially when standard treatments haven’t worked.
This study tests a new treatment for people with Crohn's disease who have lost response to ustekinumab (Stelara). It aims to see if a different dosing or additional treatment can help regain control of symptoms.
This trial tests whether a combination of two drugs (upadacitinib and ustekinumab) works better than a higher dose of ustekinumab alone for people with active Crohn's disease that hasn't responded well to previous treatments.
This study tailors ustekinumab (Stelara) treatment specifically for people with fistulizing Crohn's disease around the anus. It aims to find the best way to use this medicine to improve symptoms like pain and drainage from fistulas.
This study is for children and teens with inflammatory bowel disease (Crohn's, colitis, or indeterminate) whose previous anti-TNF medicine stopped working. It compares several newer treatments to see which works best.
This study looks at people with active Crohn's disease or ulcerative colitis starting a new type of medication (anti-TNF, ustekinumab, upadacitinib, or vedolizumab), as well as people without IBD having a routine colonoscopy. It aims to collect information to better understand how these treatments work.
Hear when a new Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.